Adherence to Once-daily and Twice-daily Direct-acting Antiviral Therapy for Hepatitis C Infection Among People With Recent Injection Drug Use or Current Opioid Agonist Therapy

被引：58

作者：

Cunningham, Evan B. ^{[1
]}

Hajarizadeh, Behzad ^{[1
]}

Amin, Janaki ^{[1
,2
]}

Litwin, Alain H. ^{[3
,4
,5
]}

Gane, Edward ^{[6
]}

Cooper, Curtis ^{[7
]}

Lacombe, Karine ^{[8
]}

Hellard, Margaret ^{[9
,10
]}

Read, Phillip ^{[1
,11
]}

Powis, Jeff ^{[12
]}

Dalgard, Olav ^{[13
,14
]}

Bruneau, Julie ^{[15
]}

Matthews, Gail, V ^{[1
,16
]}

Feld, Jordan J. ^{[17
]}

Dillon, John F. ^{[18
]}

Shaw, David ^{[19
]}

Bruggmann, Philip ^{[20
]}

Conway, Brian ^{[21
]}

Fraser, Chris ^{[22
]}

Marks, Philippa ^{[1
]}

Dore, Gregory J. ^{[1
,16
]}

Grebely, Jason ^{[1
]}

机构：

[1] Univ New South Wales, Kirby Inst, Wallace Wurth Bldg, Sydney, NSW 2052, Australia

[2] Macquarie Univ, Fac Med & Hlth Sci, Sydney, NSW, Australia

[3] Univ South Carolina, Greenville, SC USA

[4] Clemson Univ, Greenville, SC USA

[5] Prisma Hlth, Greenville, SC USA

[6] Auckland City Hosp, Auckland, New Zealand

[7] Ottawa Hosp Res Inst, Ottawa, ON, Canada

[8] Sorbonne Univ, Hop St Antoine, AP HP, Inserm UMR S1136, Paris, France

[9] Burnet Inst, Melbourne, Vic, Australia

[10] Alfred Hosp, Dept Infect Dis, Melbourne, Vic, Australia

[11] Kirketon Rd Ctr, Sydney, NSW, Australia

[12] South Riverdale Community Hlth Ctr, Toronto, ON, Canada

[13] Akershus Univ Hosp, Oslo, Norway

[14] Univ Oslo, Inst Clin Med, Oslo, Norway

[15] Ctr Hosp Univ Montreal, Montreal, PQ, Canada

[16] St Vincents Hosp, Sydney, NSW, Australia

[17] Toronto Gen Hosp, Toronto, ON, Canada

[18] Univ Dundee, Ninewells Hosp & Med Sch, Dundee, Scotland

[19] Royal Adelaide Hosp, Adelaide, SA, Australia

[20] Arud Ctr Addict Med, Zurich, Switzerland

[21] Vancouver Infect Dis Ctr, Vancouver, BC, Canada

[22] Coolaid Community Hlth Ctr, Victoria, BC, Canada

来源：

CLINICAL INFECTIOUS DISEASES | 2020年 / 71卷 / 07期

关键词：

HCV; treatment; PWID; injection drug users; OAT; HCV GENOTYPE 1; VIRUS-INFECTION; MEDICAID REIMBURSEMENT; SOFOSBUVIR; RIBAVIRIN; RESTRICTIONS; VELPATASVIR; DASABUVIR; EFFICACY;

D O I：

10.1093/cid/ciz1089

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Background. This study investigated adherence and associated factors among people with recent injection drug use (IDU) or current opioid agonist therapy (OAT) and compared once-daily to twice-daily hepatitis C virus (I ICV) direct-acting antiviral (DAA) therapy. Methods. SIMPLIFY and D3FEAT are international, multicenter studies that recruited participants with recent IDU (previous 6 months; SIMPLIFY, D3FEAT) or current OAT (D3FEAT) between March 2016 and February 2017 in 8 countries. Participants received sofosbuvir/velpatasvir (once daily; SIMPLIFY) or paritaprevir/ritonavir/ombitasvir, dasabuvir (twice daily) +/- ribavirin (D3FEAT) for 12 weeks administered in electronic blister packs. We evaluated overall adherence (proportion of prescribed doses taken) and nonadherence (<90% adherent) between dosing patterns. Results. Of 190 participants, 184 (97%) completed treatment. Median adherence was 92%, with higher adherence among those receiving once-daily vs twice-daily therapy (94% vs 87%, P = .005). Overall, 40% of participants (n = 76) were nonadherent (<90% adherent). Recent stimulant injecting (odds ratio [OR], 2.48 [95% confidence interval (CIL 1.28-4.82]), unstable housing (OR, 2.18 [95% CI, 1.01-4.70]), and twice-daily dosing (OR, 2.81 [95% CI, 1.47-5.36]) were associated with nonadherence. Adherence decreased during therapy. Sustained virologic response was high in nonadherent (89%) and adherent populations (95%, P = .174), with no difference in SVR between those who did and did not miss 7 consecutive doses (92% vs 93%, P = .897). Conclusions. This study demonstrated high adherence to once- and twice-daily DAA therapy among people with recent IDU or currently receiving OAT. Nonadherence described did not impact treatment outcomes, suggesting forgiveness to nonadherence.

引用

页码：E115 / E124

页数：10

共 31 条

[1]

Aidala AA, 2016, AM J PUBLIC HEALTH, V106, P95, DOI 10.2105/AJPH.2015.302905a

[2]

[Anonymous], 2019, WORLD DRUG REPORT 20

[3]

[Anonymous], 2016, 5 INT S HEP CAR SUBS

[4] Treatment of Hepatitis C Virus Infection Among People Who Are Actively Injecting Drugs: A Systematic Review and Meta-analysis [J].

Aspinall, Esther J. ;

Corson, Stephen ;

Doyle, Joseph S. ;

Grebely, Jason ;

Hutchinson, Sharon J. ;

Dore, Gregory J. ;

Goldberg, David J. ;

Hellard, Margaret E. .

CLINICAL INFECTIOUS DISEASES, 2013, 57 :S80-S89

[5] Restrictions for Medicaid Reimbursement of Sofosbuvir for the Treatment of Hepatitis C Virus Infection in the United States [J].

Barua, Soumitri ;

Greenwald, Robert ;

Grebely, Jason ;

Dore, Gregory J. ;

Swan, Tracy ;

Taylor, Lynn E. .

ANNALS OF INTERNAL MEDICINE, 2015, 163 (03) :215-+

[6] Belgian experience with direct acting antivirals in people who inject drugs [J].

Bielen, Rob ;

Moreno, Christophe ;

Van Vlierberghe, Hans ;

Bourgeois, Stefan ;

Mulkay, Jean-Pierre ;

Vanwolleghem, Thomas ;

Verlinden, Wim ;

Brixko, Christian ;

Decaestecker, Jochen ;

De Galocsy, Chantal ;

Janssens, Filip ;

Cool, Mike ;

Van Overbeke, Lode ;

Van Steenkiste, Christophe ;

D'heygere, Francois ;

Cools, Wilfried ;

Nevens, Frederik ;

Robaeys, Geert .

DRUG AND ALCOHOL DEPENDENCE, 2017, 177 :214-220

[7] The AUDIT alcohol consumption questions (AUDIT-C) - An effective brief screening test for problem drinking [J].

Bush, K ;

Kivlahan, DR ;

McDonell, MB ;

Fihn, SD ;

Bradley, KA .

ARCHIVES OF INTERNAL MEDICINE, 1998, 158 (16) :1789-1795

[8] The Impact of Once-Nightly Versus Twice-Daily Dosing and Baseline Beliefs About HAART on Adherence to Efavirenz-Based HAART Over 48 Weeks: The NOCTE Study [J].

Cooper, Vanessa ;

Horne, Rob ;

Gellaitry, Grace ;

Vrijens, Bernard ;

Lange, Anne-Catherine ;

Fisher, Martin ;

White, David .

JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2010, 53 (03) :369-377

[9] Adherence to sofosbuvir and velpatasvir among people with chronic HCV infection and recent injection drug use: The SIMPLIFY study [J].

Cunningham, Evan B. ;

Amin, Janaki. ;

Feld, Jordan J. ;

Bruneau, Julie ;

Dalgard, Olav ;

Powis, Jeff ;

Hellard, Margaret ;

Cooper, Curtis ;

Read, Phillip ;

Conway, Brian ;

Dunlop, Adrian J. ;

Norton, Briana ;

Litwin, Alain H. ;

Hajarizadeh, Behzad ;

Thurnheer, Maria Christine ;

Dillon, John F. ;

Weltman, Martin ;

Shaw, David ;

Bruggmann, Philip ;

Gane, Edward ;

Fraser, Chris ;

Marks, Philippa ;

Applegate, Tanya L. ;

Quiene, Sophie ;

Siriragavan, Sharmila ;

Matthews, Gail V. ;

Dore, Gregory J. ;

Grebely, Jason .

INTERNATIONAL JOURNAL OF DRUG POLICY, 2018, 62 :14-23

[10] Adherence to response-guided pegylated interferon and ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: the ACTIVATE study [J].

Cunningham, Evan B. ;

Hajarizadeh, Behzad ;

Dalgard, Olav ;

Amin, Janaki ;

Hellard, Margaret ;

Foster, Graham R. ;

Bruggmann, Philip ;

Conway, Brian ;

Backmund, Markus ;

Robaeys, Geert ;

Swan, Tracy ;

Marks, Philippa S. ;

Quiene, Sophie ;

Applegate, Tanya L. ;

Weltman, Martin ;

Shaw, David ;

Dunlop, Adrian ;

Bruneau, Julie ;

Midgard, Havard ;

Bourgeois, Stefan ;

Thurnheer, Maria Christine ;

Dore, Gregory J. ;

Grebely, Jason .

BMC INFECTIOUS DISEASES, 2017, 17

← 1 2 3 4 →